In Q4FY20, consolidated revenue declined marginally to Rs. 4,376cr, primarily impacted by weak US revenue (-25.1% YoY). However, India (Rx+Gx) business posted a 12.2% YoY growth in sales to Rs. 1,730cr. Cipla continued to perform well across key therapeutic areas, mainly due to its One India' plan of integrating 3 businesses Prescription, Trade Generics and Consumer Health. Internationally, South Africa continued its growth momentum (10.0% YoY in local currency) while holding ground in private market and OTC. The US FDA approval for generic Albuterol MDI and the successful completion of the phase 3 clinical study of generic Advair Diskus and also filing of a complex inhaler ANDA strengthened Cipla's respiratory franchise in the US...